Abstract | OBJECTIVE: METHODS: This semi-systematic review performed a study of Phase III randomized controlled trials comparing NOACs with vitamin K antagonists (VKAs) in patient with atrial fibrillation using composite end points (combination of various clinical events). The use of composite end points allowed for combining efficacy and safety outcomes, thereby comparing the differences between NOAC and warfarin therapy from a clinical perspective. RESULTS: Treatment with NOAC compared with warfarin was associated with a significant reduction in the sum of stroke or non-CNS, systemic embolism and major bleeding (odds ratio 0.87; 95% CI: 0.82-0.91). CONCLUSION: Generally, NOACs were associated with a more favorable efficacy and safety profile compared with warfarin with regard to composite end points.
|
Authors | Aida Madzak, Torben Bjerregaard Larsen, Deirdre A Lane, Gregory Y H Lip, Peter Brønnum Nielsen |
Journal | Expert review of cardiovascular therapy
(Expert Rev Cardiovasc Ther)
Vol. 13
Issue 10
Pg. 1155-63
(Oct 2015)
ISSN: 1744-8344 [Electronic] England |
PMID | 26401923
(Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Review, Systematic Review)
|
Chemical References |
- Anticoagulants
- Fibrinolytic Agents
- Vitamin K
- Warfarin
|
Topics |
- Administration, Oral
- Anticoagulants
(therapeutic use)
- Atrial Fibrillation
(complications, drug therapy)
- Embolism
(prevention & control)
- Fibrinolytic Agents
(therapeutic use)
- Hemorrhage
(epidemiology)
- Humans
- Randomized Controlled Trials as Topic
- Stroke
(prevention & control)
- Vitamin K
(antagonists & inhibitors)
- Warfarin
(therapeutic use)
|